Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels

• Juliana Velez Lujan,
• Paula A. Lengerke-Diaz,
• Chaja Jacobs,
• Eider F. Moreno-Cortes,
• Cesar A. Ramirez-Segura,
• Michael Y. Choi,
• Colin McCarthy,
• Alaina Heinen,
• Thomas J. Kipps,
• Januario E. Castro

Affiliations

Juliana Velez Lujan

UC San Diego Moores Cancer Center, San Diego, CA

Paula A. Lengerke-Diaz

Mayo Clinic, Scottsdale, AZ, USA

Chaja Jacobs

UC San Diego Moores Cancer Center, San Diego, CA

Eider F. Moreno-Cortes

Mayo Clinic, Scottsdale, AZ, USA

Cesar A. Ramirez-Segura

Mayo Clinic, Scottsdale, AZ, USA

Michael Y. Choi

UC San Diego Moores Cancer Center, San Diego, CA

Colin McCarthy

UC San Diego Moores Cancer Center, San Diego, CA

Alaina Heinen

UC San Diego Moores Cancer Center, San Diego, CA

Thomas J. Kipps

UC San Diego Moores Cancer Center, San Diego, CA

Januario E. Castro

UC San Diego Moores Cancer Center, San Diego, CA;Mayo Clinic, Scottsdale, AZ, USA